KMTS · Kestra Medical Technologies, Lt
$21.06
+4.56% last session
End-of-day data · updated 2026-07-28
Market cap
$1B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
-11.3
Dividend yield
—
Beta
—
Avg volume
0M
Employees
0K
2D change
—
5D change
5.80%
10D change
-6.55%
30D change
-13.66%
60D change
7.34%
MTD change
-13.17%
YTD change
-13.95%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — KMTS
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-21
Latest call per bank · past 12 months
Goldman Sachs
Neutral$17.00
-19.3% vs priceWells Fargo
Overweight$28.00
+33.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-21 | Oppenheimer | Initiates | Perform | $0.00 |
| 2026-07-15 | BTIG | Maintains | Buy | $30.00 → $32.00 |
| 2026-04-09 | Goldman Sachs | Maintains | Neutral | $22.00 → $17.00 |
| 2026-04-07 | BTIG | Reiterates | Buy | $32.00 |
| 2026-03-25 | BTIG | Reiterates | Buy | $32.00 |
| 2026-03-18 | BTIG | Reiterates | Buy | $32.00 |
| 2025-12-15 | Goldman Sachs | Maintains | Neutral | $22.00 → $25.00 |
| 2025-12-12 | Wells Fargo | Maintains | Overweight | $27.00 → $28.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 52 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 7.0% above the 50-day MA ($22.31).
- Price vs 200-day MA: Trading 1.4% above the 200-day MA ($23.53).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.42) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($14.46) and high ($28.01).
KMTS Price Chart
Loading chart for KMTS…
Fundamentals
About Kestra Medical Technologies, Lt
Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease through connected monitoring, therapeutic intervention, and data-driven clinical insights. The company also develops and commercializes Cardiac Recovery System platform, an integrated cardiac recovery ecosystem designed to support patients at elevated risk of sudden cardiac arrest (SCA) during vulnerable periods of recovery. Its platform provides ASSURE Wearable Cardioverter Defibrillator (WCD), which continuously monitors patient heart rhythms and automatically delivers defibrillation therapy when life-threatening ventricular arrhythmias are detected; digital patient engagement and clinical workflow solutions designed to improve patient adherence, support care coordination, and provide actionable clinical insights throughout the recovery process; and integrated platform generates continuous cardiac rhythm data and clinically actionable insights. Kestra Medical Technologies, Ltd. was founded in 2014 and is based in Kirkland, Washington.
More in Medical Instruments & Supplies
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.